Summary
PROJECT SUMMARY/ABSTRACT Type 1 diabetes (T1D) is a chronic autoimmune disease that results in destruction of pancreatic islet beta cells by autoreactive T lymphocytes. T1D is the most common form of diabetes in children less than 15 years of age. Intensive insulin therapy is the current standard of treatment for T1D. Yet, insulin treatment does not address the underlying autoimmunity present in T1D. As such, there is a critical need for T1D therapies that target autoimmunity, which will prevent beta cell loss in early stages of T1D and allow for survival of remaining beta cells in later T1D s
